Hiroyuki Yamaguchi

Dr. Hiroyuki Yamaguchi

Nagasaki University Hospital
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
HTHirokazu Taniguchi
Hirokazu Taniguchi
TYTadaaki Yamada
Tadaaki Yamada
RWRong Wang
Rong Wang
KTKeiko Tanimura
Keiko Tanimura
YAYuta Adachi
Yuta Adachi
SYSeiji Yano
Seiji Yano
A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutated lung cancer. However, some patients show intrinsic resistance and an insufficient response to osimertinib. This study showed that osimertinib stimulated AXL by inhibiting a negative feedback loop. Activated AXL was associated with EGFR and HER3 in maintaining cell survival and inducing the emergence of cells tolerant to osimertinib. AXL inhibition reduced the viability of EGFR-mutated lung cancer cells overexpressing AXL that were exposed to osimertinib. The addition of an AXL inhibitor during either the initial or tolerant phases reduced tumor size and delayed tumor re-growth compared to osimertinib alone. AXL was highly expressed in clinical specimens of EGFR-mutated lung cancers and its high expression was associated with a low response rate to EGFR-TKI. These results indicated pivotal roles for AXL and its inhibition in the intrinsic resistance to osimertinib and the emergence of osimertinib-tolerant cells.

12 January 2016 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
KFKazutaka Fukumura
Kazutaka Fukumura
MKMasahito Kawazu
Masahito Kawazu
SKShinya Kojima
Shinya Kojima
TUToshihide Ueno
Toshihide Ueno
ESEirin Sai
Eirin Sai
HMHiroyuki Mano
Hiroyuki Mano

4 February 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MKMasahito Kawazu
Masahito Kawazu
TUToshihide Ueno
Toshihide Ueno
KKKenji Kontani
Kenji Kontani
YOYoshitaka Ogita
Yoshitaka Ogita
MAMizuo Ando
Mizuo Ando
HMHiroyuki Mano
Hiroyuki Mano
Members of the RAS superfamily of small guanosine triphosphatases (GTPases) transition between GDP-bound, inactive and GTP-bound, active states and thereby function as binary switches in the regulation of various cellular activities. Whereas HRAS, NRAS, and KRAS frequently acquire transforming missense mutations in human cancer, little is known of the oncogenic roles of other small GTPases, including Ras-related C3 botulinum toxin substrate (RAC) proteins. We show that the human sarcoma cell line HT1080 harbors both NRAS(Q61K) and RAC1(N92I) mutant proteins. Whereas both of these mutants were able to transform fibroblasts, knockdown experiments indicated that RAC1(N92I) may be the essential growth driver for this cell line. Screening for RAC1, RAC2, or RAC3 mutations in cell lines and public databases identified several missense mutations for RAC1 and RAC2, with some of the mutant proteins, including RAC1(P29S), RAC1(C157Y), RAC2(P29L), and RAC2(P29Q), being found to be activated and transforming. P29S, N92I, and C157Y mutants of RAC1 were shown to exist preferentially in the GTP-bound state as a result of a rapid transition from the GDP-bound state, rather than as a result of a reduced intrinsic GTPase activity. Activating mutations of RAC GTPases were thus found in a wide variety of human cancers at a low frequency; however, given their marked transforming ability, the mutant proteins are potential targets for the development of new therapeutic agents.

1 January 2018 in International Journal of Biological Sciences
Verified
Journal Article
Open access
HSHiroaki Senju
Hiroaki Senju
AKAsuka Kumagai
Asuka Kumagai
YNYoichi Nakamura
Yoichi Nakamura
HYHiroyuki Yamaguchi
Hiroyuki Yamaguchi
KNKatsumi Nakatomi
Katsumi Nakatomi
HMHiroshi Mukae
Hiroshi Mukae
When pathogenic stresses are recognized by innate immune cells, inflammasomes are assembled and caspase-1 is activated, resulting in the conversion of pro-IL-18 into mature IL-18. Because natural killer (NK) cells express IL-18 receptors, IL-18 may play roles in immune functions of NK cells. In the present study, we examined the effect of IL-18 on NK cells derived from lung cancer patients and healthy adult volunteers. When peripheral blood NK cells were stimulated with IL-2, the cells formed clusters beginning on day 5-6 and proliferated thereafter, in which the number of NK cells increased by 10-fold in 10 days. When IL-18 was added, cell clusters were observed as early as on day 4 and NK cells proliferated vigorously. On day 10, the expansion rate was 56-fold on average, showing that IL-18 promoted the expansion of NK cells. It was also notable that IL-18 enhanced the expression of CD80, CD86, HLA-DR and HLA-DQ on NK cells, suggesting that IL-18 conferred NK cells an APC-like phenotype. When cellular cytotoxicity was determined, APC-like NK cells efficiently killed tumor cells and anti-tumor activity was augmented by the addition of tumor antigen-specific mAbs. In addition, IFN-γ was produced by APC-like NK cells in response to tumor cells, and the cytokine production was further enhanced by mAbs. Taken together, IL-18 not only promoted the expansion of NK cells, but also changed the phenotype of NK cells. IL-2/IL-18-induced NK cells might, therefore, serve as a bridge between innate immunity and adaptive immunity and be useful for cancer immunotherapy.

26 September 2013 in Leukemia
Verified
Journal Article
Closed access
PDF file
TYT Yasuda
T Yasuda
TUT Ueno
T Ueno
KFK Fukumura
K Fukumura
AYA Yamato
A Yamato
MAM Ando
M Ando
HMH Mano
H Mano

1 December 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
YOYoshihiro Ohue
Yoshihiro Ohue
KKKoji Kurose
Koji Kurose
TKTakahiro Karasaki
Takahiro Karasaki
MIMidori Isobe
Midori Isobe
TYTakaaki Yamaoka
Takaaki Yamaoka
MOMikio Oka
Mikio Oka
Programmed cell death-1 (PD-1) inhibitors effectively treat NSCLC and prolong survival. Robust biomarkers for predicting clinical benefits of good response and long survival with anti-PD-1 therapy have yet to be identified; therefore, predictive biomarkers are needed to select patients with benefits. We conducted a prospective study to explore whether serum antibody against NY-ESO-1 and/or XAGE1 cancer-testis antigens predicted primarily good clinical response and secondarily long survival with anti-PD-1 therapy for NSCLC. The serum antibody was detected by enzyme-linked immunosorbent assay, and tumor immune microenvironment and mutation burden were analyzed by immunohistochemistry and next-generation sequencing. In the discovery cohort (n = 13), six antibody-positive NSCLC cases responded to anti-PD-1 therapy (two complete and four partial responses), whereas seven antibody-negative NSCLC cases did not. Antibody positivity was associated with good response and survival, regardless of tumor programmed death ligand 1 (PD-L1) expression, mutation burden, and CD8+ T-cell infiltration. In the validation cohort (n = 75), 17 antibody-positive NSCLC cases responded well to anti-PD-1 therapy as compared with 58 negative NSCLC cases (objective response rate 65% versus 19%, p = 0.0006) and showed significantly prolonged progression-free survival and overall survival. Antibody titers highly correlated with tumor reduction rates. In the multivariate analysis, response biomarkers were tumor programmed death ligand 1 expression and antibody positivity, and only antibody positivity was a significantly better predictive biomarker of progression-free survival (hazard ratio = 0.4, p = 0.01) and overall survival (hazard ratio = 0.2, p = 0.004). Our results suggest that NY-ESO-1 and/or XAGE1 serum antibodies are useful biomarkers for predicting clinical benefits in anti-PD-1 therapy for NSCLC and probably for other cancers.